PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20946880-2	2010	In the present investigation, we analyzed whether treatment with rosuvastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, would prevent the increases in inflammatory microglia and IL-6 levels in the brain and plasma of WT and ApoE-/- mice.	Rosuvastatin Calcium	65-77	interleukin 6	Mus musculus	223-227	
28740344-7	2017	Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels.	Rosuvastatin Calcium	39-51	interleukin 6	Mus musculus	122-126	
28025996-11	2016	Rosuvastatin significantly decreased the expression levels of pro-inflammatry cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and transforming growth factor (TGF)-beta1.	Rosuvastatin Calcium	0-12	interleukin 6	Mus musculus	132-150	
27316397-7	2016	CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice.	Rosuvastatin Calcium	97-109	interleukin 6	Mus musculus	190-194	
29185103-12	2017	Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1beta and IL-6 levels.	Rosuvastatin Calcium	25-37	interleukin 6	Mus musculus	67-71	
28622591-7	2017	Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone.	Rosuvastatin Calcium	18-30	interleukin 6	Mus musculus	225-229	
23276528-8	2013	RESULTS: Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall.	Rosuvastatin Calcium	9-21	interleukin 6	Mus musculus	166-179	
22382902-13	2012	Furthermore, treatment with rosuvastatin decreased the expression levels of TNF-alpha (group H, 65.19 +- 7.06 pg/ml; group L, 108.20 +- 5.28 pg/ml; group N, 239.34 +- 11.65 pg/ml) and IL-6 (group H, 14.33 +- 2.15 pg/ml; group L, 19.67 +- 3.04 pg/ml; group N, 40.39 +- 7.17 pg/ml).	Rosuvastatin Calcium	28-40	interleukin 6	Mus musculus	184-188	
20946880-5	2010	Rosuvastatin treatment resulted in lowered plasma IL-6 levels in WT mice on a HC diet.	Rosuvastatin Calcium	0-12	interleukin 6	Mus musculus	50-54